Table 3.

Biosamples included in the study biobank and when they are obtained from participants.

Sample	Arm 2–Low risk	Arm 2–Non-low risk	Arm 3–All	SMM and SWM–4-month follow-up	SMM and SWM–6-month follow-up	MM and WM
Bone marrow
Sorted and unsorted cellsa	None	0 and 60 months	0 and 60 months	Annually	Annually	At diagnosis
Plasma	None	0 and 60 months	0 and 60 months	Annually	Annually	At diagnosis
Blood
Cell-free plasma (EDTA tube)	0 months	Annually	Annually	Every 4 months	Every 6 months	At diagnosis
Plasma (Li-Hep tubes)	0 months	Annually	Annually	Every 4 months	Every 6 months	At diagnosis
Serum (SST tubes)	0 months	Annually	Annually	Every 4 months	Every 6 months	At diagnosis
Blood RNA (PaxGene® tube)	0 months	0 months	0 months	0 months	0 months	At diagnosis
Lymphocytes (CPT tube)	0 months	0 and 60 months	0 and 60 months	0 and 60 months	0 and 60 months	At diagnosis
Urine	0 months	0 months	0 months	Annually	Annually	At diagnosis

SMM smoldering multiple myeloma, SWM smoldering Walderströms macroglobulinemia, MM multiple myeloma, WM Waldenströms macroglobulinemia.

^aBuffy coat from the bone marrow samples. Unsorted in IgM MGUS but stored as CD138+ and CD138− fractions using magnetic-activated cell sorting (MACS) in Non-IgM MGUS and LC-MGUS.